Zagani, Rachid <br/><br/>
Cyclooxygenase-2 inhibitors down-regulate osteopontin and Nr4A2-new therapeutic targets for colorectal cancers.  [electronic resource] 

 -  Gastroenterology  Oct 2009 
 - 1358-66.e1-3 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0012 
<br/><br/><label>Standard No.: </label>10.1053/j.gastro.2009.06.039  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenomatous Polyposis Coli--drug therapy<br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Cell Line, Tumor<br/>Cell Survival<br/>Colonic Polyps--drug therapy<br/>Colorectal Neoplasms--drug therapy<br/>Cyclooxygenase 2--metabolism<br/>Cyclooxygenase Inhibitors--therapeutic use<br/>DNA-Binding Proteins--genetics<br/>Down-Regulation<br/>Gene Expression Profiling--methods<br/>Gene Expression Regulation, Neoplastic<br/>Genes, APC<br/>Humans<br/>Isoxazoles--therapeutic use<br/>Lactones--therapeutic use<br/>Mice<br/>Mice, Mutant Strains<br/>Nuclear Receptor Subfamily 4, Group A, Member 2<br/>Oligonucleotide Array Sequence Analysis<br/>Osteopontin--genetics<br/>Promoter Regions, Genetic<br/>RNA Interference<br/>Signal Transduction<br/>Sulfones--therapeutic use<br/>Time Factors<br/>Transcription Factors--genetics<br/>Transfection<br/>Wnt Proteins--metabolism<br/>beta Catenin--metabolism